BioNTech (NASDAQ:BNTX) has been assigned a $130.00 target price by equities researchers at Berenberg Bank in a report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 14.72% from the stock’s current price.
BNTX has been the subject of a number of other research reports. Zacks Investment Research raised BioNTech from a “sell” rating to a “hold” rating in a report on Tuesday, March 30th. JPMorgan Chase & Co. set a $104.00 price objective on BioNTech and gave the stock a “neutral” rating in a report on Tuesday. SVB Leerink lifted their price objective on BioNTech from $97.00 to $106.00 and gave the stock a “market perform” rating in a report on Thursday, February 4th. Finally, Canaccord Genuity lifted their price objective on BioNTech from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, December 14th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. BioNTech presently has an average rating of “Hold” and an average target price of $102.00.
BioNTech stock opened at $113.32 on Tuesday. The firm has a market cap of $27.29 billion, a price-to-earnings ratio of -56.66 and a beta of -1.74. The stock has a fifty day simple moving average of $105.83 and a two-hundred day simple moving average of $100.58. BioNTech has a 12 month low of $37.00 and a 12 month high of $131.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Captrust Financial Advisors lifted its position in BioNTech by 433.3% during the fourth quarter. Captrust Financial Advisors now owns 400 shares of the company’s stock valued at $33,000 after purchasing an additional 325 shares in the last quarter. Highlander Capital Management LLC purchased a new position in shares of BioNTech in the third quarter valued at about $35,000. US Bancorp DE purchased a new position in shares of BioNTech in the fourth quarter valued at about $46,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of BioNTech in the fourth quarter valued at about $49,000. Finally, Park Capital Group purchased a new position in shares of BioNTech in the fourth quarter valued at about $50,000. Institutional investors own 10.75% of the company’s stock.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Featured Article: Blockchain
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.